More research into CNTF treatment required

Article

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

Dr Jacque L. Duncan from the Beckman Vision Center, School of Medicine, University of California, San Francisco, California, USA, led a study group in the examination of the cone photoreceptor structure and function of the 2 patients with retinitis pigmentosa and 1 patient with usher syndrome.

All patients participated in a phase II clinical trial and were treated with sustained-release CNTF delivered by an encapsulated cell technology implant in one eye and sham surgery in the other. The outcome measures were obtained using AOSLO.

The results show that outer retinal layers were significantly thicker in CNTF treated eyes than the sham-treated eyes. The findings demonstrated there were no significant changes in VA, visual field sensitivity or ERG responses. AOSLO is a sensitive way to measure disease progression and reactions to treatment in patients. A larger study is required to determine the effect of CNTF treatment in inherited retinal degenerations.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.